What the UK price tiers actually cover

Three price points cover the full range of ChondroFiller injection treatment in the UK: £3,000 for one box, £5,500 for two boxes, and £8,000 for three boxes. Every figure is all-inclusive — there are no separate consultation fees, no imaging surcharges, and no itemised billing after the appointment. Each tier covers the initial consultation, real-time ultrasound imaging, the ChondroFiller product itself, intravenous antibiotic cover, the injection procedure, and a six-week follow-up. Patients budgeting for hip cartilage treatment can therefore treat the quoted figure as the total cost, not a starting point.

These figures come from London Cartilage Clinic, which introduced ChondroFiller as an injection in the UK and publishes the only transparent price list for the treatment available from any UK provider. Because no comparable pricing has been published elsewhere, they represent the practical benchmark for any UK patient comparing options or requesting a quote from another clinic.

The same pricing tariff applies to the hip joint as to any other joint; there is no separate schedule for hip treatment. The tier a patient falls into is determined clinically — by defect size, location, and how many compartments of the hip joint are involved — rather than being a matter of choice. Most patients require one box, which places them at the £3,000 level, though larger surface areas or multi-compartment involvement may indicate two or three boxes. A clinic should not quote a final price before reviewing imaging, since the number of boxes needed — and therefore the total cost — cannot be confirmed without that assessment.

Why cost varies: how hip defect size determines which price tier applies

The ball-and-socket architecture of the hip joint means cartilage damage can present across a wide range of surface areas and locations — from a small focal lesion on the femoral head to more diffuse involvement of the acetabular rim following years of femoroacetabular impingement (FAI). That anatomical variability is what underlies the tiered pricing structure.

Each box of ChondroFiller is designed to cover focal cartilage defects up to approximately 3 cm²; a second or third box extends scaffold coverage to 6 cm² or beyond. The number of boxes required is determined entirely by defect dimensions and the number of compartments involved. Because hip cartilage damage arises through different mechanisms — FAI, acute sporting injury, repetitive stress loading, or age-related degeneration — the size and distribution of the resulting defect varies considerably between patients, even those presenting with broadly similar symptoms.

This is precisely why imaging review must precede any cost confirmation. MRI maps defect size, location, and the quality of the surrounding cartilage, all of which inform how much scaffold material is needed. A patient with a contained 2 cm² lesion on the femoral head occupies a different clinical scenario from one with multi-compartment wear across both femoral and acetabular surfaces. The entry figure applies to the former profile; the latter may indicate two or three boxes. No clinic can confirm which tier applies without first reviewing that imaging.

Getting the ChondroFiller hip injection in Lincolnshire

For patients in Lincolnshire and the wider non-London catchment, a practical question follows from any pricing comparison: where can the treatment actually be accessed? Lincolnshire Hip provides a local answer — ChondroFiller hip injections are available at clinics in Grantham and Sleaford, with no requirement to travel to Harley Street.

The treating clinician at both sites is Professor Paul Lee, the specialist who introduced ChondroFiller as an injection in the UK and leads London Cartilage Clinic, an ICRS Teaching Centre of Excellence. Choosing a regional appointment carries no clinical compromise; the expertise, the product, and the assessment process are the same as those available in London.

Suitability for the ChondroFiller hip injection is mapped through a structured four-lens framework: physics (the mechanical state of the joint and how load is distributed across the hip), chemistry (the biological environment inside the joint, including the degree of inflammation present), biology (tissue quality and the patient's own healing capacity), and timing (where the patient sits on their progression from early cartilage loss to more advanced wear). Rather than producing a binary yes or no, this assessment identifies the most appropriate point on the treatment pathway — a ChondroFiller injection, keyhole surgery, or a combination of the two — for each individual presentation.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for initial hip assessment.

Who the ChondroFiller hip injection is suitable for

Age is not a barrier to the ChondroFiller hip injection, and neither is an advanced wear grade — with one important qualification.

The injection is an outpatient procedure taking 30–45 minutes, delivered under real-time ultrasound guidance with no general anaesthetic and no surgical incision. There is no upper age limit, and being described as 'bone on bone' does not automatically exclude a patient from consideration. Eligibility is determined by defect type, location, and imaging findings — not by age or wear grade alone. The product functions as a top-down collagen scaffold that coats worn joint surfaces, making it relevant in presentations ranging from focal post-injury lesions to Kellgren-Lawrence Grade III or IV degeneration in selected patients.

Candidates most likely to be suitable include those with focal cartilage defects in the hip — whether arising from femoroacetabular impingement (FAI), acute injury, or early degenerative change — where the surrounding cartilage retains enough integrity to support scaffold integration.

The honest boundary is diffuse, end-stage hip osteoarthritis with no residual cartilage architecture. In that setting, cartilage repair is unlikely to be appropriate, and a candid discussion about joint preservation versus replacement becomes the more relevant conversation. A thorough imaging review at assessment is what distinguishes these two groups reliably.

Funding the treatment: self-pay and private insurance

ChondroFiller injection is a self-funded private procedure; it is not available on the NHS.

Private medical insurance may contribute to the cost under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). In clinical practice, pre-authorisation has been reported most consistently with Bupa, Aviva, and WPA — though this does not mean those insurers will always approve a claim. Outcomes depend on individual policy terms, the stated indication, and the insurer's coverage position, which can change. The billing codes give patients something concrete to raise with their insurer or broker when exploring what, if anything, their policy will contribute.

Written pre-authorisation must be obtained before treatment begins. Insurers do not cover costs retrospectively, and partial cover is a realistic outcome — some policies will meet part of the episode fee while leaving a patient contribution. Before committing to a booking, it is worth confirming in writing exactly which elements are included: consultation, ultrasound imaging, the product itself, and the six-week follow-up are all part of the all-inclusive price, so the insurer should be asked to specify coverage for the procedure as a whole.

The information above reflects practice as of late 2025 and may be subject to change.

Clinical outcomes that support the investment

Published clinical results give some tangible context for the cost. In hip-specific studies, patients treated with ChondroFiller injection recorded a Harris Hip Score improvement of approximately +33 points — a gain large enough to shift many patients from significant functional restriction into meaningful day-to-day recovery. Harris Hip Score is a validated measure of pain, mobility, and daily function, so a 33-point uplift represents a clinically material change rather than a marginal statistical signal.

Structural repair has been confirmed on MRI using MOCART scoring, with values ranging from 70 to 87 across published studies. MOCART assesses the degree of defect filling, tissue integration, and surface congruency; scores in this range indicate that the scaffold has supported substantial cartilage regeneration, not merely symptom masking.

Globally, over 19,000 ChondroFiller procedures have been performed across multiple joints. A reported complaint rate of approximately 0.06% reflects a strong safety profile across that caseload — a figure worth noting alongside the CE Class III regulatory designation, which requires a higher level of clinical evidence than lower-class devices.

One honest limitation deserves naming: the most extensive published datasets come from knee studies, and hip-specific long-term follow-up from UK centres is still accumulating. The hip evidence base — including the +33 Harris Hip Score gain and the MOCART range — supports the treatment for suitable patients, and the global volume of over 19,000 cases provides meaningful procedural confidence, but patients should understand that hip data continues to develop.